Mousavi Seyed Mohsen, Mohagheghi Mohammad Ali, Mousavi-Jerrahi Alireza, Nahvijou Azin, Seddighi Zahra
Department of Community Medicine, Faculty of Medicine, Liver and Gastro intestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Asian Pac J Cancer Prev. 2008 Apr-Jun;9(2):275-8.
Breast Cancer is the second most common cancer among Iranian women. This study was conducted to define the outcome of breast cancer which had been registered by Tehran Cancer Registry.
All Tehranian breast cancer which registered from 1998 to 2001 was selected; the repeated cases were excluded according to their common name, family name, and Father's name. A simple data collection form was used to complete the demographic and diagnostic time and survival situation of the cases by five educated technicians with using phone interviews with patients or their families. All data were entered in Access file and then exported to SPSS-11.5, for descriptive and analytic analysis, p value was significant under 0.05. Since there were some cases had not phone number or the phone numbers were not accessible; 360 cases were selected with Simple Random Sampling and their hospital files were reviewed to complete the demographic and location situations data. Kaplan- Meier regression model was used for computing the survival.
Of the 7098 records, 4416 records were interviewed by phone. This phone interviews were succeeded among 2358 cases; Tehranian and other cities were defined in 986 and 1372 records respectively. The Tehranian cases were estimated 36.9% (CI95%: 31.9%-41.8%). The mean age of patients was 51.3+/-12.5, 31.4% of them was under 40 years old, the incidence rate of breast cancer in 100,000 women was estimated 17.09 CI95% (15.67-18.50). Infiltrating duct carcinoma was the most morphology (68.4%). Right, left, and both breast involvement were seen in 48.6% CI95% (43.4%-53.8%), 46.1% CI95 %( 41.0%-51.2%), 0.3% CI95%(0.1%-0.5%) respectively. The tumor size over 2 centimeters was seen in 63.6% of cases at diagnostic time. Lymphadenopathy and metastasis were seen in 48.3% CI95% (43.1%-53.5%), and 19.7% CI95% (15.6%-23.8%) of cases. The median survival was 5.0 years CI95% (4.9 years-5.1 years).
This retrospective survival study was shown the seven years follow up from 1998 to 2005, women which were diagnosed in 1998, 1999, 2000, and 2001; 55.9%, 61.4%, 60.3%, 66% were alive respectively. Interventional projects for increasing the survival rate, early detection, and effective treatment of breast cancer were recommended.
乳腺癌是伊朗女性中第二常见的癌症。本研究旨在确定德黑兰癌症登记处登记的乳腺癌患者的预后情况。
选取1998年至2001年在德黑兰登记的所有乳腺癌病例；根据患者的常用名、姓氏和父亲姓名排除重复病例。由五名受过培训的技术人员通过电话采访患者或其家属，使用简单的数据收集表来完善病例的人口统计学信息、诊断时间和生存情况。所有数据录入Access文件，然后导出到SPSS - 11.5进行描述性和分析性分析，p值在0.05以下具有统计学意义。由于部分病例没有电话号码或无法接通，通过简单随机抽样选取360例病例，并查阅其医院档案以完善人口统计学和肿瘤位置情况的数据。采用Kaplan - Meier回归模型计算生存率。
在7098条记录中，通过电话采访了4416条记录。其中2358例电话采访成功；分别在986条和1372条记录中确定了德黑兰及其他城市的病例。德黑兰的病例估计占36.9%（95%置信区间：31.9% - 41.8%）。患者的平均年龄为51.3±12.5岁，其中31.4%年龄在40岁以下，每10万名女性中乳腺癌的发病率估计为17.09（95%置信区间：15.67 - 18.50）。浸润性导管癌是最常见的病理类型（68.4%）。右侧、左侧及双侧乳腺受累的比例分别为48.6%（95%置信区间：43.4% - 53.8%）、46.1%（95%置信区间：41.0% - 51.2%）、0.3%（95%置信区间：0.1% - 0.5%）。诊断时肿瘤大小超过2厘米的病例占63.6%。48.3%（95%置信区间：43.1% - 53.5%）的病例出现淋巴结病，19.7%（95%置信区间：15.6% - 23.8%）的病例出现转移。中位生存期为5.0年（95%置信区间：4.9年 - 5.1年）。
这项回顾性生存研究显示，对1998年至2005年进行了七年随访，1998年、1999年、2000年和2001年诊断的女性患者，其生存率分别为55.9%、61.4%、60.3%、66%。建议开展干预项目以提高乳腺癌的生存率、实现早期检测和有效治疗。
